This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Learn more here.
Paul R.  Kirchgraber net worth and biography

Paul Kirchgraber Biography and Net Worth

Dr. Paul R. Kirchgraber serves as Executive Vice President and Chief Executive Officer - Covance Drug Development of the Company. From July 2018 until then, Dr. Kirchgraber served as Senior Vice President and head of Covance’s clinical trial testing solutions, and he served as Senior Vice President of Central Laboratories from April 2015 until July 2018. He served as Vice President and General Manager of Americas with Covance Central Laboratories from 2012 until 2015. Prior to that Dr. Kirchgraber served as Vice President Global Laboratory Operations and Medical Affairs with Covance Central Laboratory from 2009 – 2015. Prior to joining the Company, Dr. Kirchgraber also served at Quintiles Laboratories Ltd as Vice President and Global Medical Director where he was responsible for oversight of wholly owned laboratories in the U.S., Singapore, South Africa, India, and China and as Senior Director of Laboratory Services/ North American Medical Director where he had operational responsibility for laboratory and specimen management departments and was the medical director of the U.S. laboratory. Dr. Kirchgraber received his medical degree from Cornell University and his Master’s degree in Business Administration from Binghamton University, and he holds three board certifications from the American Board of Pathology.

What is Paul R. Kirchgraber's net worth?

The estimated net worth of Paul R. Kirchgraber is at least $2.84 million as of May 19th, 2023. Dr. Kirchgraber owns 12,946 shares of Laboratory Co. of America stock worth more than $2,838,281 as of February 26th. This net worth evaluation does not reflect any other assets that Dr. Kirchgraber may own. Learn More about Paul R. Kirchgraber's net worth.

How do I contact Paul R. Kirchgraber?

The corporate mailing address for Dr. Kirchgraber and other Laboratory Co. of America executives is 358 South Main Street, BURLINGTON NC, 27215. Laboratory Co. of America can also be reached via phone at (336) 229-1127 and via email at [email protected]. Learn More on Paul R. Kirchgraber's contact information.

Has Paul R. Kirchgraber been buying or selling shares of Laboratory Co. of America?

Paul R. Kirchgraber has not been actively trading shares of Laboratory Co. of America within the last three months. Most recently, Paul R. Kirchgraber sold 4,300 shares of the business's stock in a transaction on Friday, May 19th. The shares were sold at an average price of $216.91, for a transaction totalling $932,713.00. Following the completion of the sale, the chief executive officer now directly owns 12,946 shares of the company's stock, valued at $2,808,116.86. Learn More on Paul R. Kirchgraber's trading history.

Who are Laboratory Co. of America's active insiders?

Laboratory Co. of America's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Brian Caveney (EVP), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Peter Neupert (Director), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Laboratory Co. of America's active insiders.

Are insiders buying or selling shares of Laboratory Co. of America?

During the last year, insiders at the medical research company sold shares 10 times. They sold a total of 51,793 shares worth more than $11,208,958.28. The most recent insider tranaction occured on February, 21st when CFO Glenn A Eisenberg sold 34,504 shares worth more than $7,451,828.88. Insiders at Laboratory Co. of America own 0.7% of the company. Learn More about insider trades at Laboratory Co. of America.

Information on this page was last updated on 2/21/2024.

Paul R. Kirchgraber Insider Trading History at Laboratory Co. of America

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/19/2023Sell4,300$216.91$932,713.0012,946View SEC Filing Icon  
2/21/2023Sell8,000$250.58$2,004,640.009,069View SEC Filing Icon  
5/6/2021Sell2,500$276.55$691,375.007,844View SEC Filing Icon  
11/4/2020Sell1,500$214.14$321,210.007,698View SEC Filing Icon  
See Full Table

Paul R. Kirchgraber Buying and Selling Activity at Laboratory Co. of America

This chart shows Paul R Kirchgraber's buying and selling at Laboratory Co. of America by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Laboratory Co. of America Company Overview

Laboratory Co. of America logo
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics and Labcorp Drug Development. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications to enable patients to check test results; and online applications for MCOs and accountable care organizations; and end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves MCOs, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Read More

Today's Range

Now: $219.24
Low: $218.01
High: $221.10

50 Day Range

MA: $223.81
Low: $215.65
High: $232.56

2 Week Range

Now: $219.24
Low: $174.20
High: $234.09

Volume

94,597 shs

Average Volume

693,754 shs

Market Capitalization

$18.61 billion

P/E Ratio

46.95

Dividend Yield

1.31%

Beta

1.04
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Full details and steps to take here.